News & Media

Mydecine's CEO Josh Bartch talks therapeutic medicine funding and market listings with the editor-in-chief of IPO-Edge.

A listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.

A wide range of government and private non-dilutive funding sources are available for the disorders being addressed by NeuroPharm.

‍The two industry leaders among psychedelic stocks have already carved out their own followings among psychedelic stock investors.

Mindleap's digital telehealth mobile application for mental coaching and wellbeing is now available for download.

Green Market Report reports Mindleap Health has launched a digital health platform that combines telehealth with mood, emotion, and habit tracking.

High Times article details a new Mindleap app that connects mental health professionals with people using psychedelics.

In recent years mushrooms left their dark, hidden habitats to jump into the spotlight of consumer markets.

MIG shareholders have agreed to extend lock-up restrictions that were due to be released on September 6, 2020, for an additional 120 days.

Mydecine Innovations Group Inc. has closed its previously announced acquisition of NeuroPharm Inc., a developer of natural health, psychedelic-based treatments for post-traumatic stress disorder and other serious mental health disorders.

Industry newsletter The Trip Report highlighted Mydecine as one of the few companies planning to produce psilocybin from natural products.

The Denver-based company says the new milestone will advance global research for medical psilocybin as depression rises during the pandemic.

Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.

Mydecine Innovations Group Inc. announces two new strategic advisors to the company's Scientific Advisory Board.

Mydecine™ becomes first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade, naturally derived psilocybin.

NeuroPharm Inc. was recently covered in Forbes for its ground-breaking psilocybin clinical trials for treatment of posttraumatic stress disorder (PTSD)

Mydecine Innovations Group Inc. is pleased to provide a corporate update regarding recent advancements and achievements that continues to add shareholder value

Psychedelics-based treatments developer NeuroPharm Inc. recently announced it would be collaborating on clinical trials for the treatment of posttraumatic stress disorder (PTSD)

Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness

Recently it was announced that ebbu's Director of Research, Robert Roscow, M.A., would leave a cannabis industry conglomerate to become the Chief Science Officer of the leading psychedelic startup ...

Mydecine Innovations Group Inc. is pleased to announce that they have hired former Red Bull marketing executive, Jim Gunning, as the Company’s new Chief Marketing Officer (“CMO”).

Denver-based Mydecine Innovations Group Inc. continues to expand its fungi footprint deeper into North America.

There is a need for new antidepressants with a mechanism of action different from that of SSRIs and SNRIs to improve efficacy across several symptoms

Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans

Mydecine Innovations Group Inc. announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.

Mydecine Innovations Group Inc. announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.

Mydecine Innovations Group Inc. announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.

NEW YORK: Despite the various stigmas associated with psychedelics, there is a growing acceptance of using psychedelic drugs specifically to treat depression.

NEW YORK, July 6, 2020 /PRNewswire/ -- The political push for the legalization of psychedelic products is now underway.

NEW YORK: Depression and PTSD are serious psychiatric disorders which happen to share some similar symptoms. Either disorder might cause trouble sleeping, anger over little things, or a loss of interest in people or things.

Mydecine Innovations Group Inc. is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.

Mydecine Innovations Group Inc. is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.

So much interest in psychedelics medicine that some analysts see the industry bringing in $6.85 billion by 2027 .

The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases and it operates in one of the most diverse and complex markets.

NEW YORK: The trend of cannabis legalization in several countries is one of the key factors driving the market's growth.

Mydecine Innovations Group Inc. is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.

Mydecine Innovations Group Inc.(OTC: MYCOF) (CSE: MYCO), is pleased to announce the addition of two key strategic advisors to the company’s Scientific Advisory Committee.

Featuring Our Corporate News Recap on “Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist.”

Mydecine Innovations Group Inc. is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.

Oregon-founded psychedelics company Silo Wellness announced June 17 the singing of a binding letter of intent to combine its business operations with Yukoterre Resources Inc.

Mydecine Innovations Group Inc. (OTCPK:MYCOF or MYCO in Canada) throws words like “earth-shattering” around in the press releases.

Mydecine Innovations Group Inc. announced breaking news yesterday that, "it has signed a definitive share exchange agreement with Mindleap Health Inc.

Mydecine Innovations Group Inc. is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc.

Mydecine is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. for the acquisition of a 100% interest.

Lifestyle sciences company Mydecine Innovations Group Inc. confirmed Wednesday it has inked a deal with MindLeap.

“Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth Platform.”

Mydecine Innovations Group Inc. is a parent company which operates innovative product divisions in the Naturally Sourced Therapies (NST) space.

Hosted In The University Of Alberta Faculty Of Pharmacy And Pharmaceutical Sciences With Full Access To GMP Capacity And Health Canada Licenses

Mydecine Innovations Group Inc. is pleased to announce the establishment of a research division agreement with Applied Pharmaceutical Innovation ("API")

Mydecine Innovations Group Inc. (NLBIF) -- formerly known as NewLeaf. The company just signed an agreement with the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences.

Mydecine (MYCO.CN) (NLBIF) is quickly upping its fungi authority. The mycology-focused company has signed an agreement with Applied Pharmaceutical Innovation (API)

Mydecine Innovations Group Inc. (OTC: NLBIF) (CSE: MYCO), is pleased to announce the establishment of a research division agreement with Applied Pharmaceutical Innovation (“API”)

Strategically Positioned on Therapies for Military, Veterans, Front-Line Personnel Globally to cope with Mental Health & Well-Being

Mydecine Innovations Group to Acquire NeuroPharm Inc. Strategically Positioned on Therapies for Military, Veterans, Front-Line Personnel Globally to cope with Mental Health & Well-Being

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Mydecine Innovations Group to Acquire NeuroPharm Inc..”

Mydecine is pleased to announce it has signed a non-binding Letter of Intent June 9, 2020 to acquire NeuroPharm Inc.

Mydecine is pleased to announce it has signed a non-binding Letter of Intent June 9, 2020 to acquire NeuroPharm Inc.

The small-cap markets have been invaded with a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space and for researching psychedelic medicine.

NEW YORK: There have been several important developments in the psychedelics market in recent years that indicate a change in public sentiment around such products.

Bottled water producer The Alkaline Water Company named former Primo Water executive Nicholas Salimbene to the role of director of operations.

NEW YORK: Data indicates that psychedelics are gaining popularity. For example, in 2019, the Global Drug Survey collaborated with psychedelic researchers to examine the acceptability of psychedelic products and other drugs such as MDMA (ecstasy) and

Canadian CBD company Mydecine Brands Inc. is changing its name to Mydecine Innovations Group Inc. to reflect its focus on developing strains of psychedelic mushrooms.

Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB) announced breaking news earlier this week that, "it has changed its name from NewLeaf Brands Inc. to Mydecine Innovations Group Inc. and its ticker symbol from 'NLB' to 'MYCO'. Subject to approval of the Ca

SinglePoint, Inc. (OTCMKTS:SING) has reported revenues of $1.075 million (up 300%) in Q1 2020. The projects developed in Q4 2019 and the acquisition of Direct Solar helped the company report stellar growth in Q1.

Cannabis company NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) announced a set of measures this week that mark a shift in the company’s focus to muhsrooms and therapeutic psychedelics.

Mydecine Brands (CSE: NLB) this morning announced that it has completed its wholly owned and operated R&D and product development lab ...

Mydecine Brands Inc. (OTC: NLBIF) (CSE: NLB), soon to put into effect its name change to Mydecine Group, is pleased to announce the completion of its wholly-owned and operated world class R&D Lab and Facilities focused on the mycology of the fungtion

("Mydecine Brands" or the "Company"), soon to put into effect its name change to Mydecine Group, is pleased to announce the completion of its wholly-owned and operated world class R&D Lab and Facilities...

Mydecine Brands Inc. (CSE: NLB) (OTC: NLBIF) reported Tuesday it has completed its 7,500 square-feet lab in Denver, Colorado.

CFN Enterprises Aims to Capitalize on an Industry That is Projected to Grow at a 16.3% Compound Annual Growth Rate Between 2020 and 2027 to Reach $6.86 Billion...

Newleaf Brands Inc. this week announced that it has appointed Jamaican Dr. Aubrey Oliver ND, RBT to be its newest advisor.

NewLeaf Brands had signed a share swap agreement with Levee Street Holdings, LLC ("Levee Street") to purchase 50% of Levee Street for CAD $450,000 in common shares.

Mydecine Brands had signed a share swap agreement with Levee Street Holdings, LLC (“Levee Street”) to purchase 50% of Levee Street for CAD $450,000 in common shares.

Mydecine Brands had signed a share swap agreement with Levee Street Holdings, LLC (“Levee Street”) to purchase 50% of Levee Street for CAD $450,000 in common shares.

The path that psychedelics are taking to de-regulation is reminiscent to that of cannabis. Over the past several years, the cannabis industry has reached several milestones to almost completely redefine itself.

Mydecine Brands Inc. (OTC: NLBIF) (CSE: NLB) is pleased to announce that it has officially appointed Dr. Aubrey Oliver ND, RBT to be its newest advisor.

Mydecine Brands (OTCPK:NLBIF +4.3%) to sell ~6.7M units at C$0.30 per unit, via private placement for gross proceeds of up to C$2M

https://www.prnewswire.co.uk/news-releases/newleaf-brands-agrees-to-acquire-mindleap-health-inc-digital-health-platform-to-combine-mood-emotion-and-habit-tracking-with-tele-health-in-the-fight-against-mental-illness-861027672.html

Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB) just announced breaking news that, "it has signed a non-binding Letter of Intent ("LOI") with Mindleap Health Inc. ("Mindleap"), dated May 20, 2020, pursuant to which NewLeaf Brands will acquire, by way of

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Mydecine Brands Wholly-owned Subsidiary, Mydecine Group

("NewLeaf Brands" oder das "Unternehmen") freut sich bekannt zu geben, dass seine hundertprozentige Tochtergesellschaft Mydecine Group ("Mydecine") am Aufbau eines Ressourcen-Ökosystems arbeitet, mit dem das Potenzial von Pilzen als Wellnessprodukte